FX 201 - Flexion Therapeutics

Drug Profile

FX 201 - Flexion Therapeutics

Alternative Names: FX201 - Flexion; GQ 203

Latest Information Update: 18 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baylor College of Medicine
  • Developer Flexion Therapeutics
  • Class Anti-inflammatories; Antirheumatics; Gene therapies; Non-opioid analgesics
  • Mechanism of Action Gene transference; Interleukin-1-Receptor-Antagonist-Protein-Stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Osteoarthritis

Most Recent Events

  • 08 Mar 2018 Flexion Therapeutics has issued patents for FX 201 in China and Europe, and pending patents for FX 201 in Australia, Eurasia, India, Japan and USA, licensed from Baylor College of Medicine
  • 13 Dec 2017 FX 201 licensed to Flexion
  • 13 Dec 2017 Preclinical trials in Osteoarthritis in USA (intra-articular)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top